You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 10, October 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Vitreoretinal Surgery
 •Alert me on articles by topic

Argatroban Inhibits Intraocular Fibrin Formation After Vitrectomy in Rabbits

Takatoshi Maeno, MD; Yasuo Tano, MD; Tomiya Mano, MD; Hisashi Takenaka, MD

Arch Ophthalmol. 2000;118:1401-1405.

Objectives  To examine whether the specific thrombin inhibitor argatroban can prevent anterior chamber, pupillary area, and anterior vitreous fibrin formation after vitrectomy and lensectomy in rabbits.

Methods  Argatroban was infused into the vitreous cavities of Japanese albino rabbits for 5 minutes after pars plana vitrectomy and lensectomy. Slitlamp microscopy and indirect ophthalmoscopy were performed at postoperative hours 0.5, 1, 2, 3, and 6, and at postoperative days 1, 2, 3, and 7, and the amounts of fibrin formation in the anterior chamber, pupillary area, and anterior vitreous were scored from grade 0 to 4.

Results  Argatroban prevented fibrin formation from 0.5 hours postoperatively in a dose-dependent manner. In the eyes treated with 0.01% argatroban, the median score for postoperative fibrin formation was significantly less than that in control eyes between hours 1 and 3 (hour 1, P = .02; hour 2, P = .005; and hour 3, P = .003); the eyes treated with 0.003% argatroban also had significantly less fibrin than control eyes between 1 and 2 hours (hour 1, P = .005; hour 2, P = .03).

Conclusion  These results indicate that argatroban inhibits intraocular fibrin formation in an experimental rabbit model.

Clinical Relevance  Argatroban may be useful clinically in cases that often produce fibrin postoperatively, such as proliferative vitreoretinopathy and proliferative diabetic retinopathy.


From the Tane Memorial Eye Hospital (Drs Maeno, Mano, and Takenaka) and the Department of Ophthalmology, Osaka University Medical School (Dr Tano), Osaka, Japan.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thrombin Inhibitor Reduces Leukocyte-Endothelial Cell Interactions and Vascular Leakage after Scatter Laser Photocoagulation
Musashi et al.
IOVS 2005;46:2561-2566.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.